Next Article in Journal
Prediction of Adrenocortical Carcinoma Relapse and Prognosis with a Set of Novel Multigene Panels
Next Article in Special Issue
The CBP/β-Catenin Antagonist, ICG-001, Inhibits Tumor Metastasis via Blocking of the miR-134/ITGB1 Axis-Mediated Cell Adhesion in Nasopharyngeal Carcinoma
Previous Article in Journal
Interobserver Reliability and the Sigmoid Takeoff—An Interobserver Study
Previous Article in Special Issue
Proteomic and Transcriptomic Profiling Reveals Mitochondrial Oxidative Phosphorylation as Therapeutic Vulnerability in Androgen Receptor Pathway Active Prostate Tumors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 11
10.3390/cancers14112804
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors

Cancers 2022, 14(11), 2804; https://doi.org/10.3390/cancers14112804
by Claudia Piombino and Laura Cortesi *
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Cancers 2022, 14(11), 2804; https://doi.org/10.3390/cancers14112804
Submission received: 16 May 2022 / Revised: 2 June 2022 / Accepted: 3 June 2022 / Published: 5 June 2022
(This article belongs to the Special Issue A Deeper Dive into Signaling Pathways in Cancers)

Round 1

Reviewer 1 Report

I actually do not have anything to comment on in this review. It is well written, easy to follow, includes clear explanations in text and figures. Overall, it is comprehensive and contributes a lot to the knowledge in this field.

Author Response

Many thanks, it is a great pleasure to receive such positive comment.

Reviewer 2 Report

Fig. 2 is similar to Fig. 1 of Cortesi, L., Piombino, C., & Toss, A. (2021). Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?. Journal of personalized medicine, 11(4), 245. https://doi.org/10.3390/jpm11040245.

Please cite the ref.

 

The authors mention cancers those have mutation of BRACA 1 and 2. How many percentages of cancers have the mutations?

Author Response

Many thanks for the positive comment.

I included the reference "Cortesi, L., Piombino, C., & Toss, A. (2021). Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?. Journal of personalized medicine, 11(4), 245."

In the introduction, data regarding prevalence of BRCA1/2 mutations in breast, ovarian, pancreatic, and prostate cancers have been added.

Reviewer 3 Report

In this manuscript entitled “Insights into the molecular mechanisms of resistance to PARP inhibitors” Piombino and Cortsesi provide a comprehensive review of the literature regarding the molecular mechanisms of primary and secondary resistance to PARP inhibitors.

The topic is very interesting and there are currently only few published studies related to resistance on PARP1 inhibitors. However, the manuscript is well structured and written and manages to provide a comprehensive review of the related mechanisms.

Minor comments:

1)      Page 10, please correct the paragraph title (hypermethylation).

2)      Future perspectives: A table with information related to clinical trials that combine PARP inhibitors with other agents would help to summarize the current efforts to battle resistance to PARP inhibitors

Author Response

Many thanks for the positive feedback. I corrected the title of paragraph at page 10. Since there are 111 ongoing clinical trials investigating the combination of PARPi with immunotherapies and other agents, I added a supplementary table (S1) with the first 100 results of the reasearch "PARP inhibitor AND combination" from clinicaltrials.gov

Back to TopTop